Speaker Profile

Ph.D., Founder & CEO, AgeX Therapeutics, Inc.

Biography
Michael D. West founded the company in 2017 to develop therapeutics related to human aging. He was previously CEO/Co-CEO of regenerative medicine company BioTime Inc., for ten years. Prior to that he was Chairman and CEO of Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma in 2016 for $379 Million. In 1990 Dr. West founded Geron Corp., where he created the research consortium that led to the first isolation of human embryonic stem cells. Dr. West is the author of numerous papers in peer-reviewed scientific journals as well as “The Immortal Cell: One Scientist’s Quest to Solve the Mystery of Human Aging” (Doubleday, 2003). He has appeared as a guest on NBC’s “Meet the Press” and has testified before the U.S. Congress on the potential life-extending benefits of regenerative medicine.


Emerging Therapeutics Showcase:
AgeX Therapeutics, Inc.

AgeX Therapeutics developments novel therapeutics targeting human aging, developing medicines designed to address large unmet medical needs.

 Session Abstract – PMWC Silicon Valley


The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.